Crizotinib - Molecular Therapy for Lung Cancer;Crizotinib - Molekulare Therapie des Lungenkarzinoms

Pneumologie

Volumn 67, Issue 4, 2013, Pages 205-208

  Groschel A ^a   Warth, A ^b   Reinmuth, N ^c  

^a MVZ Ambulantes Aachener Zentrum für Lungenheilkunde   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Lungenclinic Grosshansdorf ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ECHINODERM; FUSION GENE; GENE REARRANGEMENT; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MICROTUBULE; MOLECULAR THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84876105720     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0032-1326365     Document Type: Article

References (29)

1. Soda M., Choi Y. L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature: 2007; 448 561 566 (Pubitemid 47206930)
2. Perner S., Wagner P. L., Demichelis F. et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia: 2008; 10 298 302 (Pubitemid 351328588)
3. Inamura K., Takeuchi K., Togashi Y. et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol: 2008; 3 13 17
4. Shaw A. T., Yeap B. Y., Mino-Kenudson M. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol: 2009; 27 4247 4253
5. Sasaki T., Rodig S. J., Chirieac L. R. et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer: 2010; 46 1773 1780
6. Boland J. M., Erdogan S., Vasmatzis G. et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol: 2009; 40 1152 1158
7. Wong D. W., Leung E. L., So K. K. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer: 2009; 115 1723 1733
8. Inamura K., Takeuchi K., Togashi Y. et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol: 2009; 22 508 515
9. Rodig S. J., Mino-Kenudson M., Dacic S. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res: 2009; 15 5216 5223
10. Jokoji R., Yamasaki T., Minami S. et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol: 2010; 63 1066 1070
11. Koivunen J. P., Mermel C., Zejnullahu K. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res: 2008; 14 4275 4283
12. Sanders H. R., Li H. R., Bruey J. M. et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet: 2011; 204 45 52
13. Penzel R., Schirmacher P., Warth A. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol: 2012; 7 1198 1199
14. Rikova K., Guo A., Zeng Q. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell: 2007; 131 1190 1203 (Pubitemid 350235027)
15. Takeuchi K., Choi Y. L., Togashi Y. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res: 2009; 15 3143 3149
16. Wong D. W., Leung E. L., Wong S. K. et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer: 2011; 117 2709 2718
17. Salido M., Pijuan L., Martinez-Aviles L. et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol: 2011; 6 21 27
18. Doebele R. C., Aisner D. L., Le A. T. et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. J Clin Oncol: 2012; 30 7504
19. Kwak E. L., Bang Y. J., Camidge D. R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med: 2010; 363 1693 1703
20. Yi E. S., Boland J. M., Maleszewski J. J. et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol: 2011; 6 459 465
21. Takeuchi K., Choi Y. L., Soda M. et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res: 2008; 14 6618 6624
22. Lin E., Li L., Guan Y. et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res: 2009; 7 1466 1476
23. Mino-Kenudson M., Chirieac L. R., Law K. et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res: 2010; 16 1561 1571
24. Scagliotti G., Stahel R. A., Rosell R. et al. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. Eur J Cancer: 2012; 48 961 973
25. Camidge D. R., Bang Y-J, Kwak E. L. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol: 2012; 13 1011 1019
26. Zhang S., Wang F., Keats J. et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des: 2011; 78 999 1005
27. Doebele R. C., Pilling A. B., Aisner D. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res: 2012; 18 1472 1482
28. Katayama R., Shaw A. T., Khan T. M. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med: 2012; 4 120ra17
29. Sasaki T., Koivunen J., Ogino A. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res: 2011; 71 6051 6060